1. Home
  2. MSDL vs IDYA Comparison

MSDL vs IDYA Comparison

Compare MSDL & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MSDL
  • IDYA
  • Stock Information
  • Founded
  • MSDL 2019
  • IDYA 2015
  • Country
  • MSDL United States
  • IDYA United States
  • Employees
  • MSDL N/A
  • IDYA N/A
  • Industry
  • MSDL
  • IDYA Biotechnology: Pharmaceutical Preparations
  • Sector
  • MSDL
  • IDYA Health Care
  • Exchange
  • MSDL NYSE
  • IDYA Nasdaq
  • Market Cap
  • MSDL 1.9B
  • IDYA 2.2B
  • IPO Year
  • MSDL N/A
  • IDYA 2019
  • Fundamental
  • Price
  • MSDL $21.61
  • IDYA $23.15
  • Analyst Decision
  • MSDL Buy
  • IDYA Strong Buy
  • Analyst Count
  • MSDL 7
  • IDYA 13
  • Target Price
  • MSDL $21.67
  • IDYA $53.67
  • AVG Volume (30 Days)
  • MSDL 354.2K
  • IDYA 890.1K
  • Earning Date
  • MSDL 01-01-0001
  • IDYA 02-18-2025
  • Dividend Yield
  • MSDL 9.25%
  • IDYA N/A
  • EPS Growth
  • MSDL N/A
  • IDYA N/A
  • EPS
  • MSDL N/A
  • IDYA N/A
  • Revenue
  • MSDL N/A
  • IDYA $3,922,000.00
  • Revenue This Year
  • MSDL $1,597.39
  • IDYA N/A
  • Revenue Next Year
  • MSDL $15.28
  • IDYA $273.42
  • P/E Ratio
  • MSDL N/A
  • IDYA N/A
  • Revenue Growth
  • MSDL N/A
  • IDYA N/A
  • 52 Week Low
  • MSDL $19.05
  • IDYA $22.10
  • 52 Week High
  • MSDL $24.18
  • IDYA $47.74
  • Technical
  • Relative Strength Index (RSI)
  • MSDL 62.87
  • IDYA 39.49
  • Support Level
  • MSDL $20.23
  • IDYA $22.10
  • Resistance Level
  • MSDL $21.17
  • IDYA $24.06
  • Average True Range (ATR)
  • MSDL 0.35
  • IDYA 1.04
  • MACD
  • MSDL 0.07
  • IDYA -0.15
  • Stochastic Oscillator
  • MSDL 94.85
  • IDYA 24.19

About MSDL MORGAN STANLEY DIRECT LENDING FUND

Morgan Stanley Direct Lending Fund is a fund whose investment objective is to achieve attractive risk-adjusted returns via current income and, to a lesser extent, capital appreciation by investing predominantly in directly originated senior secured term loans issued by U.S. middle-market companies backed by private equity sponsors. It invests predominantly in directly originated senior secured term loans including first lien senior secured term loans including unitranche loans and second lien senior secured term loans, with the balance of the investments expected to be in higher-yielding assets such as mezzanine debt, unsecured debt, equity investments and other opportunistic asset purchases.

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.

Share on Social Networks: